SGMT vs SKYE

Sagimet Biosciences Inc. - Seri vs Skye Bioscience, Inc. — Valuation Comparison 2026

SGMT

Pharmaceutical Preparations
Sagimet Biosciences Inc. - Seri
Quality
3.8
out of 10
Value Trap
24
SAFE
Price
$7.29
Last close
Models
7/13
Active
VS

SKYE

Pharmaceutical Preparations
Skye Bioscience, Inc.
Quality
3.6
out of 10
Value Trap
30
LOW
Price
$0.78
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType SGMT Fair ValueSGMT Upside SKYE Fair ValueSKYE Upside
Bayesian DCF Intrinsic $2.15 -70.5% $0.20 -73.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.92 -87.4% $0.08 -90.5%
Dynamic NAV Asset-Based $1.96 -73.1% $1.84 +137.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SGMT vs SKYE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SGMT vs SKYE — Which Stock Is More Undervalued?

SGMT scores higher with a 3.8/10 quality rating vs SKYE's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Sagimet Biosciences Inc. - Seri (SGMT) and Skye Bioscience, Inc. (SKYE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SGMT currently trades at $7.29 with a QOC of 3.8/10, while SKYE trades at $0.78 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).